Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Relay Therapeutics stock | $31.14

Learn how to easily invest in Relay Therapeutics stock.

Relay Therapeutics Inc is a biotechnology business based in the US. Relay Therapeutics shares (RLAY) are listed on the NASDAQ and all prices are listed in US Dollars. Relay Therapeutics employs 203 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Relay Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RLAY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Relay Therapeutics stock price (NASDAQ: RLAY)

Use our graph to track the performance of RLAY stocks over time.

Relay Therapeutics shares at a glance

Information last updated 2021-10-25.
Latest market close$31.14
52-week range$25.72 - $64.37
50-day moving average $33.21
200-day moving average $32.93
Wall St. target price$53.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.81

Buy Relay Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Relay Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Relay Therapeutics price performance over time

Historical closes compared with the close of $31.14 from 2021-10-26

1 week (2021-10-20) -0.26%
1 month (2021-09-27) -16.76%
3 months (2021-07-27) -2.87%
6 months (2021-04-27) -6.99%
1 year (2020-10-27) -19.99%
2 years (2019-10-23) N/A
3 years (2018-10-23) N/A
5 years (2016-10-23) N/A

Relay Therapeutics financials

Revenue TTM $84.5 million
Gross profit TTM $82.7 million
Return on assets TTM -12.09%
Return on equity TTM -50.79%
Profit margin -279.91%
Book value $6.68
Market capitalisation $3.4 billion

TTM: trailing 12 months

Shorting Relay Therapeutics shares

There are currently 10.6 million Relay Therapeutics shares held short by investors – that's known as Relay Therapeutics's "short interest". This figure is 5.5% up from 10.0 million last month.

There are a few different ways that this level of interest in shorting Relay Therapeutics shares can be evaluated.

Relay Therapeutics's "short interest ratio" (SIR)

Relay Therapeutics's "short interest ratio" (SIR) is the quantity of Relay Therapeutics shares currently shorted divided by the average quantity of Relay Therapeutics shares traded daily (recently around 709604.90921318). Relay Therapeutics's SIR currently stands at 14.87. In other words for every 100,000 Relay Therapeutics shares traded daily on the market, roughly 14870 shares are currently held short.

However Relay Therapeutics's short interest can also be evaluated against the total number of Relay Therapeutics shares, or, against the total number of tradable Relay Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Relay Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Relay Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.1745% of the tradable shares (for every 100,000 tradable Relay Therapeutics shares, roughly 175 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Relay Therapeutics.

Find out more about how you can short Relay Therapeutics stock.

Relay Therapeutics share dividends

We're not expecting Relay Therapeutics to pay a dividend over the next 12 months.

Relay Therapeutics overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D.

Frequently asked questions

What percentage of Relay Therapeutics is owned by insiders or institutions?
Currently 3.599% of Relay Therapeutics shares are held by insiders and 83.99% by institutions.
How many people work for Relay Therapeutics?
Latest data suggests 203 work at Relay Therapeutics.
When does the fiscal year end for Relay Therapeutics?
Relay Therapeutics's fiscal year ends in December.
Where is Relay Therapeutics based?
Relay Therapeutics's address is: 399 Binney Street, Cambridge, MA, United States, 02139
What is Relay Therapeutics's ISIN number?
Relay Therapeutics's international securities identification number is: US75943R1023

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site